IRB #
STUDY00022730
Title
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III
Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with
Estrogen Receptor-Positive, HER2-Negative Advanced Breast
Cancer Who Have Not Received Any Systemic Treatment for
Advanced Disease
Principal Investigator
Eric Anderson
Study Purpose
The study is intended to show how safe and effective the combination of AZD9833 with palbociclib is in treating advanced/metastatic breast cancer compared to the alternative standard of care treatment (anastrozole in combination with palbociclib).
Medical Condition(s)
ER-positive, HER2-negative Advanced/Metastatic Breast Cancer
Eligibility Criteria
18 years or older
ER-positive, HER2-negative breast cancer
Previously untreated with any systemic anti-cancer therapy for locoregionally recurrent or metastatic ER+ disease
Age Range
18 - 101
Healthy Volunteers Needed
No
Duration of Participation
You will receive the study drugs for as long as your cancer does not get worse or you do not have bad side effects. After you are done getting treated with the study drugs, we may contact you every 12 weeks until the study closes to see how you are doing and to ask about your cancer.
Minors Included
No
Contact
Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080
Sponsor
AstraZeneca
Recruitment End
03/31/2031
Compensation Provided
No
Go Back